| Title: |
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. ; INTERACTIONS OF POSACONAZOLE AND FLUCYTOSINE AGAINST CRYPTOCOCCUS NEOFORMANS |
| Authors: |
BARCHIESI, FRANCESCO; GIACOMETTI, Andrea; SCALISE, Giorgio; Schimizzi AM; Najvar LK; Bocanegra R; Caselli F; Di Cesare S; Giannini D; Di Francesco LF; Carle F; Graybill JR |
| Contributors: |
Barchiesi, Francesco; Schimizzi, Am; Najvar, Lk; Bocanegra, R; Caselli, F; Di Cesare, S; Giannini, D; Di Francesco, Lf; Giacometti, Andrea; Carle, F; Scalise, Giorgio; Graybill, Jr |
| Publisher Information: |
American Society for Microbiology:PO Box 11127:Birmingham, AL 35201:(800)633-4931, (205)995-1567, EMAIL: asm.nonmembers.subs@ebsco.com, INTERNET: http://www.asm.org, Fax: (205)995-1588 |
| Publication Year: |
2001 |
| Collection: |
Università Politecnica delle Marche: IRIS |
| Subject Terms: |
posaconazole; Antifungal agent; antifungal resistance; nosocomial infection; Drug Synergism |
| Description: |
A checkerboard methodology, based on standardized methods proposed by the National Committee for Clinical Laboratory Standards for broth microdilution antifungal susceptibility testing, was applied to study the in vitro interactions of flucytosine (FC) and posaconazole (SCH 56592) (FC-SCH) against 15 isolates of Cryptococcus neoformans. Synergy, defined as a fractional inhibitory concentration (FIC) index of 4.0, was not observed. The in vitro efficacy of combined therapy was confirmed by quantitative determination of the CFU of C. neoformans 486, an isolate against which the FC-SCH association yielded a synergistic interaction. To investigate the potential beneficial effects of this combination therapy in vivo, we established two experimental murine models of cryptococcosis by intracranial or intravenous injection of cells of C. neoformans 486. At 1 day postinfection, the mice were randomized into different treatment groups. One group each received each drug alone, and one group received the drugs in combination. While combination therapy was not found to be significantly more effective than each single drug in terms of survival, tissue burden experiments confirmed the potentiation of antifungal activity with the combination. Our study demonstrates that SCH and FC combined are significantly more active than either drug alone against C. neoformans in vitro as well in vivo. These findings suggest that this therapeutic approach could be useful in the treatment of cryptococcal infections. |
| Document Type: |
article in journal/newspaper |
| File Description: |
STAMPA |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/11302795; info:eu-repo/semantics/altIdentifier/wos/WOS:000168240300006; volume:45; issue:5; firstpage:1355; lastpage:1359; numberofpages:5; journal:ANTIMICROBIAL AGENTS AND CHEMOTHERAPY; https://hdl.handle.net/11566/74007; https://hdl.handle.net/11566/31299 |
| DOI: |
10.1128/AAC.45.5.1355-1359.2001 |
| Availability: |
https://hdl.handle.net/11566/74007; https://hdl.handle.net/11566/31299; https://doi.org/10.1128/AAC.45.5.1355-1359.2001 |
| Accession Number: |
edsbas.B95F4339 |
| Database: |
BASE |